MA42935B1 - Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations - Google Patents

Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations

Info

Publication number
MA42935B1
MA42935B1 MA42935A MA42935A MA42935B1 MA 42935 B1 MA42935 B1 MA 42935B1 MA 42935 A MA42935 A MA 42935A MA 42935 A MA42935 A MA 42935A MA 42935 B1 MA42935 B1 MA 42935B1
Authority
MA
Morocco
Prior art keywords
antigen
antibodies
binding
human
cells
Prior art date
Application number
MA42935A
Other languages
English (en)
Other versions
MA42935A (fr
Inventor
Douglas Macdonald
Eric Smith
Robert Babb
Gang Chen
Lauric Haber
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA42935A publication Critical patent/MA42935A/fr
Publication of MA42935B1 publication Critical patent/MA42935B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps qui se lient à cd3 avec peu ou pas d'affinité de liaison détectable et leurs procédés d'utilisation. Selon certains modes de réalisation, les anticorps de l'invention se lient au cd3 humain avec une faible affinité et induisent la prolifération de lymphocytes t humains, et par conséquent induisent la destruction, à travers les lymphocytes t, de cellules tumorales avec une grande efficacité. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à l'antigène bispécifique comprenant un premier domaine de liaison à l'antigène qui se lie spécifiquement au cd3 humain avec peu ou pas d'affinité de liaison détectable dans un essai in vitro, et une seconde molécule de liaison à l'antigène qui se lie spécifiquement à un antigène associé à une tumeur chez l'homme. Dans certains modes de réalisation, les molécules de liaison à l'antigène bispécifique selon la présente invention sont capables d'inhiber la croissance de tumeurs exprimant l'antigène cible, par exemple psma. Les anticorps et les molécules de liaison à l'antigène bispécifique de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée positivement régulée ou induite est souhaitée et/ou thérapeutiquement bénéfique. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers ou d'autres maladies où l'immunothérapie, c'est-à-dire. L'immunomodulation de cellule effectrice est garantie.
MA42935A 2015-09-23 2016-09-23 Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations MA42935B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222605P 2015-09-23 2015-09-23
PCT/US2016/053525 WO2017053856A1 (fr) 2015-09-23 2016-09-23 Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations

Publications (2)

Publication Number Publication Date
MA42935A MA42935A (fr) 2018-08-01
MA42935B1 true MA42935B1 (fr) 2022-02-28

Family

ID=57130447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42935A MA42935B1 (fr) 2015-09-23 2016-09-23 Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations

Country Status (28)

Country Link
US (3) US20180355038A1 (fr)
EP (1) EP3353212B1 (fr)
JP (3) JP7023231B2 (fr)
KR (1) KR102777500B1 (fr)
CN (1) CN108290951B (fr)
AU (1) AU2016325630B2 (fr)
BR (1) BR112018005445A2 (fr)
CA (1) CA2999385A1 (fr)
CY (1) CY1124944T1 (fr)
DK (1) DK3353212T3 (fr)
EA (1) EA201890785A1 (fr)
ES (1) ES2901133T3 (fr)
HR (1) HRP20220133T8 (fr)
HU (1) HUE057683T2 (fr)
IL (1) IL258036B (fr)
LT (1) LT3353212T (fr)
MA (1) MA42935B1 (fr)
MD (1) MD3353212T2 (fr)
MX (1) MX2018003403A (fr)
MY (1) MY195059A (fr)
PL (1) PL3353212T3 (fr)
PT (1) PT3353212T (fr)
RS (1) RS62859B1 (fr)
SI (1) SI3353212T1 (fr)
SM (1) SMT202200050T1 (fr)
TW (2) TWI783914B (fr)
WO (1) WO2017053856A1 (fr)
ZA (1) ZA201801673B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
ES2823033T3 (es) 2015-05-28 2021-05-05 Genentech Inc Ensayo basado en células para detectar homodímeros anti-CD3
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
US11530277B2 (en) 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
EP3559035A1 (fr) 2016-12-21 2019-10-30 TeneoBio, Inc. Anticorps à chaîne lourde uniquement anti-bcma
EP3409322A1 (fr) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Procédés de traitement
US20180371089A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
EA039842B1 (ru) * 2017-09-14 2022-03-18 Ридженерон Фармасьютикалз, Инк. Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство
BR112020004977A2 (pt) * 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
EP3732199A1 (fr) * 2017-12-27 2020-11-04 TeneoBio, Inc. Anticorps spécifiques de l'hétérodimère cd3-delta/epsilon
CN119143875A (zh) 2018-06-21 2024-12-17 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
FI3817770T3 (fi) 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
AU2019356573B2 (en) 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
KR20210099614A (ko) * 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
TWI821474B (zh) 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
KR20210104836A (ko) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
WO2020132024A1 (fr) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
EP3941941A1 (fr) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Anticorps multispécifiques egfr x cd28
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP7743314B2 (ja) * 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
EP3986933A1 (fr) * 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
WO2020264200A1 (fr) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Fragments de liaison à l'antigène cd3 et compositions les comprenant
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
MX2022001942A (es) 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
EP4048701A4 (fr) * 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Molécules de liaison anti-cd40 et anticorps bispécifiques les comprenant
JP7693672B2 (ja) 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12686725B2 (en) 2020-05-05 2026-07-21 Mythic Therapeutics, Inc. Anti-DLL3 antibodies and methods of use
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
CA3202891A1 (fr) 2021-01-28 2022-08-04 Kara Olson Compositions et methodes de traitement du syndrome de liberation de cytokines
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
WO2022233956A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant de manière spécifique à prame
WO2023097219A2 (fr) * 2021-11-24 2023-06-01 Adimab, Llc Anticorps anti-idiotypes
EP4499683A1 (fr) 2022-03-29 2025-02-05 NGM Biopharmaceuticals, Inc. Agents de liaison ilt3 et cd3 et leurs procédés d'utilisation
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN114685675B (zh) * 2022-04-27 2023-02-03 深圳市汉科生物工程有限公司 双特异性抗体及其在治疗癌症中的用途
WO2024012513A1 (fr) * 2022-07-13 2024-01-18 Hansoh Bio Llc Anticorps, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée
EP4598958A1 (fr) 2022-10-05 2025-08-13 Amgen Inc. Polythérapies comprenant des thérapies de redirection de lymphocytes t et des anticorps agonistes anti-il-2r ou des fragments de ceux-ci
IL319818A (en) 2022-10-10 2025-05-01 Regeneron Pharma Methods for reducing alloantibody levels in patients requiring solid organ transplantation
WO2024088987A1 (fr) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
JP2026508624A (ja) 2023-03-13 2026-03-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｃｄ２２×抗ｃｄ２８分子でがんを治療する方法
JP2026524012A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法
JP2026524011A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法
EP4791786A1 (fr) * 2023-10-09 2026-08-19 Janux Therapeutics, Inc. Anticorps ciblant steap-1 et cd3, leurs utilisations
WO2025131077A1 (fr) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 Anticorps multi-spécifique anti-cd3 et son utilisation
WO2025199278A2 (fr) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène multispécifiques masquées avec agents de liaison clivables
WO2025199352A2 (fr) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Anticorps spécifiques du membre 2 de la famille des transporteurs de solutés 34 (slc34a2)
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2025240670A2 (fr) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anticorps anti-pd-1 et molécules de liaison associées et procédés et utilisations associés
WO2026050255A2 (fr) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Protéines se liant à l'antigène anti-slc3a2-apis et leurs procédés d'utilisation
WO2026076201A2 (fr) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de production de protéines thérapeutiques par filtration tangentielle à passage unique pour la concentration en ligne et la réduction volumique de groupes de production
WO2026096576A1 (fr) 2024-10-30 2026-05-07 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène multispécifiques se liant à psma et 4-1bb et leurs procédés d'utilisation
WO2026132368A1 (fr) 2024-12-20 2026-06-25 Veraxa Biotech Gmbh Anticorps anti-cd3 améliorés

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
CA2437958C (fr) 2001-03-09 2018-10-30 University Of Chicago Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc.gamma. a faible affinite
JP2005510470A (ja) * 2001-09-28 2005-04-21 エリューシス セラピューティクス，インコーポレーテッド 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
EP1740946B1 (fr) 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
US20120189643A1 (en) 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
WO2006074399A2 (fr) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules de liaison multispecifiques comprenant des peptides de connexion
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006304387A1 (en) 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
EP2463305B1 (fr) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Anticorps pour OX-2/CD200 et utilisations associées
DE102006005968A1 (de) 2006-02-08 2007-08-09 Bühler AG Siebvorrichtung für Kontrollsiebung
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2006380A4 (fr) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd Anticorps agoniste dirige contre le recepteur de la thrombopoietine humaine
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CA2689895A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Anticorps monovalents non glycosyles
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
CA2714296A1 (fr) 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Anticorps anti-c5ar humanises
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JP5798036B2 (ja) 2008-11-07 2015-10-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
CA2745439C (fr) 2008-12-03 2019-10-15 Genmab A/S Variants d'anticorps comportant des modifications dans la region constante
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2780221A1 (fr) 2009-11-04 2011-05-12 Fabrus Llc Procedes pour l'optimisation d'anticorps basee sur la maturation d'affinite
IT1396532B1 (it) 2009-11-25 2012-12-14 Pieraccini Cuffia per protesi di arto e protesi comprendente detta cuffia
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
TW201136010A (en) 2010-01-21 2011-10-16 Gs Yuasa Int Ltd Negative electrode plate using in lead storage cell, fabricating method thereof, and lead storage cell
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
CA2798120A1 (fr) 2010-04-30 2011-11-03 Paul P. Tamburini Anticorps dont l'antigenicite pour l'humain est reduite
EP2585828A4 (fr) 2010-06-25 2014-03-12 Glaxo Group Ltd Méthodes de traitement de patients souffrant de maladies se rapportant au système immunitaire
SI3339323T1 (sl) 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
SG191233A1 (en) 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US20140370012A1 (en) 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2013157105A1 (fr) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 Anticorps humain spécifique de mucine 5ac et son utilisation
SG10201609535TA (en) * 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
BR112015000798A2 (pt) 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
DE102012214441B4 (de) * 2012-08-14 2020-08-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Messverfahren
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015006824A2 (pt) * 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014054804A1 (fr) 2012-10-05 2014-04-10 協和発酵キリン株式会社 Composition de protéine hétérodimère
MX2015003616A (es) * 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
BR112016000666A2 (pt) 2013-07-12 2017-10-03 Zymeworks Inc Constructos de ligação de antígeno cd3 e cd19 biespecíficos
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｈｅｒ２抗体及び使用方法
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
GB201506407D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
KR102520731B1 (ko) * 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
TW202504917A (zh) 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
KR20230047214A (ko) 2019-07-26 2023-04-06 벨로3디, 인크. 3차원 물체 형상화에 대한 품질 보증
MX2022001942A (es) * 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.

Also Published As

Publication number Publication date
JP2018537516A (ja) 2018-12-20
US20260234256A1 (en) 2026-08-13
TWI784917B (zh) 2022-11-21
WO2017053856A1 (fr) 2017-03-30
PT3353212T (pt) 2022-01-05
IL258036A (en) 2018-05-31
HK1258304A1 (en) 2019-11-08
EP3353212B1 (fr) 2021-11-03
CN108290951A (zh) 2018-07-17
EA201890785A1 (ru) 2018-10-31
TWI783914B (zh) 2022-11-21
KR102777500B1 (ko) 2025-03-11
US12577304B2 (en) 2026-03-17
SMT202200050T1 (it) 2022-03-21
HUE057683T2 (hu) 2022-05-28
LT3353212T (lt) 2021-12-27
MD3353212T2 (ro) 2022-03-31
MY195059A (en) 2023-01-05
SI3353212T1 (sl) 2022-01-31
TW202241514A (zh) 2022-11-01
TW201726713A (zh) 2017-08-01
DK3353212T3 (da) 2021-12-20
JP2022064886A (ja) 2022-04-26
MA42935A (fr) 2018-08-01
CA2999385A1 (fr) 2017-03-30
EP3353212A1 (fr) 2018-08-01
ES2901133T3 (es) 2022-03-21
AU2016325630B2 (en) 2022-11-17
AU2016325630A1 (en) 2018-04-26
RS62859B1 (sr) 2022-02-28
ZA201801673B (en) 2022-12-21
BR112018005445A2 (pt) 2018-10-09
US20180355038A1 (en) 2018-12-13
HRP20220133T1 (hr) 2022-04-15
HRP20220133T8 (hr) 2022-05-13
CY1124944T1 (el) 2023-01-05
PL3353212T3 (pl) 2022-03-28
US20210253701A1 (en) 2021-08-19
IL258036B (en) 2022-09-01
MX2018003403A (es) 2018-05-28
JP2023154021A (ja) 2023-10-18
JP7695877B2 (ja) 2025-06-19
CN108290951B (zh) 2022-04-01
KR20180050412A (ko) 2018-05-14
JP7023231B2 (ja) 2022-02-21

Similar Documents

Publication Publication Date Title
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MA53168B1 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
PH12021551238A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
EA202090372A1 (ru) Универсальные соединения авт и их применение
WO2020077276A3 (fr) Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
WO2022081718A8 (fr) Anticorps anti-récepteur de chimiokine c-c 8 (ccr8) et leurs procédés d'utilisation
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
EP4309740A3 (fr) Anticorps anti-cd3, molécules bispécifiques de liaison à l'antigène se liant à cd3 et cd20 et leurs utilisations
JP2018052979A5 (fr)
JP2017537972A5 (fr)
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
WO2021003050A3 (fr) Agent de liaison à cd38 et utilisations associées
CR20230245A (es) Moléculas de unión a gucy2c y sus usos
WO2023129819A3 (fr) Anticorps à haute affinité à domaine unique et leurs méthodes d'utilisation
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
EA202190314A1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения
MA42523B1 (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations